Promega and Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, are partnering, the companies recently announced.

According to a release, the strategic co-marketing agreement will help deliver integrated molecular testing solutions designed to enhance safety, efficiency and flexibility across a wide range of diagnostic settings. The collaboration will bring together Longhorn’s validated PrimeStore® Molecular Transport Medium (MTM) and Promega’s Maxwell® automated nucleic extraction platform.

“Together, these technologies streamline the workflow from sample collection to high-quality nucleic acid purification without compromising on safety or performance,” Promega Director of Applied Markets Julie Yang said in a statement.

The two companies will showcase their combined technologies at the Association for Diagnostics & Laboratory Medicine conference in Chicago from July 29-31.